Novo Nordisk's Foundation Just Staged a Corporate Coup—and Investors Aren't Happy
COPENHAGEN — Something extraordinary happened at Novo Nordisk on Friday. The company's controlling foundation didn't just win a shareholder vote. It seized the boardroom.
Lars Rebien Sørensen now chairs both the foundation and the company itself. That's never happened before in Novo's hundred-year history. And it's costing shareholders dearly—$10 billion in market value has evaporated since this drama began.
The 71-year-old former CEO got his approval at an extraordinary meeting, though not everyone was thrilled about it. Norway's massive sovereign wealth fund? They either opposed the move or sat it out entirely. You don't see that kind of rebellion often, especially not in buttoned-up Scandinavia.
This vote caps off a brutal month of corporate warfare. Seven independent directors walked out in October. They couldn't agree on how fast Novo needed to change course. Now the foundation—which controls 77 percent of votes despite owning just a quarter of the equity—has installed its own people and rewritten the rules of the game.
Why the Panic? The Weight-Loss Market Just Turned Upside Down
Sørensen isn't sugarcoating things. The obesity drug world has been flipped on its head in twelve months flat. What worked before doesn't work anymore.
"The market environment Novo Nordisk faces today is drastically different from just one year ago," Sørensen told shareholders. He's defending a messy purge that pushed out chair Helge Lund and accelerated changes the old guard wanted to delay until 2026.
Here's the problem. Eli Lilly's Zepbound is beating Wegovy in U.S. prescriptions. Supply chain disasters have cost Novo market share they might never win back. Then there's the Metsera fiasco—a $9 billion bidding war gone wrong that spawned two lawsuits from Pfizer and caught antitrust regulators' attention.
The old governance model—arm's-length foundation, independent board, consensus decision-making—looked great on paper. Rating agencies loved it. But Sørensen argues it's now a straitjacket when competitors are moving at warp speed.
Helge Lund's resignation letter was diplomatic but pointed. He said consensus "could not be reached" on governance principles. Translation? The foundation wanted power, not partnership.
So What's an Investor Supposed to Think?
Novo's trading at twelve times forward earnings now. That's half what Lilly commands. Professional investors are wrestling with a tough question: is this a smart intervention by a committed long-term owner, or the start of something uglier?
The optimistic view goes like this. The foundation isn't some private equity vulture looking for a quick flip. It needs Novo's dividends forever—they fund medical research in perpetuity. Nobody cares more about long-term cash generation.
Sørensen himself ran Novo brilliantly from 2000 to 2016. He knows this business cold, which the previous board arguably didn't. He's promised to bring in directors with "deep pharmaceutical and possibly over-the-counter experience" within eighteen months. That signals they're thinking about Novo as a consumer health powerhouse, not just a research lab.
But the skeptical case is equally compelling. Concentrating this much power in one person violates every independence principle minority shareholders hold dear. The Metsera mess—where Novo torpedoed Pfizer's deal, bid the price into the stratosphere, then walked away—suggests they're willing to take risks no rational board would approve.
If the foundation starts treating Novo as a vehicle for strategic ambitions beyond pure shareholder value, that valuation discount might stick around permanently.
What Happens Next Matters More Than Ever
Right now investors are basically buying slowed-but-still-dominant GLP-1 revenue streams. Plus they're getting a lottery ticket that maybe—just maybe—the foundation's urgency produces better U.S. execution and faster drug development.
The fact that Norges Bank and other sophisticated investors protested tells you something. They see wider possibilities ahead. Could go really well or really badly.
Watch these signposts. Does the board rebuild bring credible independents or foundation cronies? Does dealmaking after Metsera show restraint or more recklessness? Can CEO Karsten Knudsen—whom Sørensen calls a "pragmatic leader"—claw back Wegovy's lost ground against Lilly in the next year?
Sørensen says he'll only serve "two to three years" at most. He's already planning succession at the foundation level. If that's true, maybe this centralization is temporary wartime footing, not permanent structure.
But if promises slip and this arrangement becomes permanent? Then Novo's governance discount becomes baked into the stock forever. And that gap between its valuation and Lilly's may never, ever close.
NOT INVESTMENT ADVICE